1
|
Gil M, Gama V. Emerging mitochondrial-mediated mechanisms involved in oligodendrocyte development. J Neurosci Res 2023; 101:354-366. [PMID: 36461887 PMCID: PMC9851982 DOI: 10.1002/jnr.25151] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 10/19/2022] [Accepted: 11/22/2022] [Indexed: 12/05/2022]
Abstract
Oligodendrocytes are the myelinating glia of the central nervous system and are generated after oligodendrocyte progenitor cells (OPCs) transition into pre-oligodendrocytes and then into myelinating oligodendrocytes. Myelin is essential for proper signal transmission within the nervous system and axonal metabolic support. Although the intrinsic and extrinsic factors that support the differentiation, survival, integration, and subsequent myelination of appropriate axons have been well investigated, little is known about how mitochondria-related pathways such as mitochondrial dynamics, bioenergetics, and apoptosis finely tune these developmental events. Previous findings suggest that changes to mitochondrial morphology act as an upstream regulatory mechanism of neural stem cell (NSC) fate decisions. Whether a similar mechanism is engaged during OPC differentiation has yet to be elucidated. Maintenance of mitochondrial dynamics is vital for regulating cellular bioenergetics, functional mitochondrial networks, and the ability of cells to distribute mitochondria to subcellular locations, such as the growing processes of oligodendrocytes. Myelination is an energy-consuming event, thus, understanding the interplay between mitochondrial dynamics, metabolism, and apoptosis will provide further insight into mechanisms that mediate oligodendrocyte development in healthy and disease states. Here we will provide a concise overview of oligodendrocyte development and discuss the potential contribution of mitochondrial mitochondrial-mediated mechanisms to oligodendrocyte bioenergetics and development.
Collapse
Affiliation(s)
- M Gil
- Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA
- Neuroscience Graduate Program, Vanderbilt University, Nashville, TN, USA
- Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA
| | - V Gama
- Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA
- Neuroscience Graduate Program, Vanderbilt University, Nashville, TN, USA
- Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA
- Vanderbilt Center for Stem Cell Biology, Vanderbilt University, Nashville, TN, USA
| |
Collapse
|
2
|
Algaba A, Romero S, Granja A, Garza D, Aller M, Barrero S, Guerra I, Gil M, Pizarro N, Ruiz P, Prieto S, Hernández B, Pou A, Bermejo F. Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2023. [PMCID: PMC9910024 DOI: 10.1016/j.gastre.2022.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Objective To study the serological response (SR) and tolerability of COVID-19 vaccine in patients with inflammatory bowel disease (IBD) and its relation with IBD treatment and type of vaccine. Methods Observational, cross-sectional study in patients with IBD vaccinated against COVID-19 without known previous infection. SR was analyzed by the determination of IgG antibodies against the S1 subunit. Safety was studied using a questionnaire to identify adverse effects (AE). Results 280 patients with IBD were included. Type of vaccines: Comirnaty® 68.8%; Spikevax® 10.8%, Vaxzevria® 18.3%, Ad26.COV2-S® 2.2%. 51.3% had AE, being 100% mild. 65% developed IgG antibodies after vaccination. The SR was higher for vaccines with mRNA technology (100% Spikevax®, 68.5% Comirnaty®) compared to those based on adenovirus vector (38.0% Vaxzevria®, 33.3% Ad26.COV2-S®) (P < .001). In the multivariate analysis, SR was related to age (<60 years; OR: 3.8, 95% CI 1.9–7.0; P < .001). The SR in patients with aminosalicylates was 65.4%, 61.4% with immunosuppressants, 65.8% with anti-TNF, and 68.7% with non-anti-TNF biologicals (P = .9). Conclusions One third of patients with IBD did not develop antibodies with the initial vaccination against SARS-CoV-2. The SR to vaccines based on mRNA technology was higher, and it was related to age (higher in younger patients). Immunosuppressants and biologicals did not decrease SR. More than half of the patients presented AD, being mild in all cases.
Collapse
Affiliation(s)
- Alicia Algaba
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain,Corresponding author
| | - Sara Romero
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Alicia Granja
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Daniel Garza
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Mar Aller
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Sara Barrero
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Iván Guerra
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Marina Gil
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Nazaret Pizarro
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Paloma Ruiz
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Santiago Prieto
- Servicio de Laboratorio, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Belén Hernández
- Servicio de Farmacia, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Aranzazu Pou
- Servicio de Farmacia, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - Fernando Bermejo
- Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Madrid, Spain
| |
Collapse
|
3
|
Ariza-Prota M, Pérez-Pallarés J, Fernández-Fernández A, García-Alfonso L, Cascón JA, Torres-Rivas H, Fernández-Fernández L, Sánchez I, Gil M, García-Clemente M, López-González F. EBUS-guided transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: safety, feasibility and diagnostic yield – experience in 50 cases. ERJ Open Res 2023; 9:00448-2022. [PMID: 37077551 PMCID: PMC10107076 DOI: 10.1183/23120541.00448-2022] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Accepted: 12/29/2022] [Indexed: 01/27/2023] Open
Abstract
BackgroundEndobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is the technique of choice in the study of mediastinal and hilar lesions; however, it can be affected by the insufficiency of intact biopsy samples, which might decrease its diagnostic yield for certain conditions, thus requiring re-biopsies or additional diagnostic procedures such as mediastinoscopy when probability of malignancy remains high.ObjectivesOur objectives were to 1) attempt to reproduce this technique in the same conditions that we performed EBUS-TBNA, that is, in the bronchoscopy suite and under moderate sedation; 2) describe the method used for its execution; 3) determine its feasibility by accessing different lymph node stations applying our method; 4) analyze the diagnostic yield and its complications.MethodsProspective study of 50 patients who underwent EBUS-TBNA and EBUS-guided TMC in a single procedure using a 22-G TBNA needle and a 1.1 mm cryo-probe subsequently between January and August 2022. Patients with mediastinal lesions greater than 1 cm were recruited and EBUS-TBNA and TMC were performed in the same lymph node station.ResultsThe diagnostic yield was 82% and 96% for TBNA and transbronchial mediastinal cryobiopsy, respectively. Diagnostic yields were similar for sarcoidosis, while cryobiopsy was more sensitive than TBNA in lymphomas and metastatic lymph nodes. As for complications, there was no pneumothorax and in no case was there significant bleeding. There were no complications during the procedure or in the follow-up of these patients.ConclusionsTMC following our method is a minimally invasive, rapid, and safe technique that can be performed in a bronchoscopy suite under moderate sedation, with a higher diagnostic yield than EBUS-TBNA, especially in cases of lymphoproliferative disorders and mestastatic lymph nodes, or when more biopsy sample is needed for molecular determinations.
Collapse
|
4
|
Gonzalez-Ramiro H, Parrilla I, Cambra J, Gonzalez-Plaza A, Gil M, Cuello C, Martinez E, Rodriguez-Martinez H, Martinez C. 190 The combination of oestrus synchronisation and superovulation treatments negatively impact embryo viability through the downregulation of Wnt/β-catenin signalling genes in the porcine endometrium. Reprod Fertil Dev 2022. [DOI: 10.1071/rdv35n2ab190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
|
5
|
Montecinos S, Gil M, Tognana S, Salgueiro W, Amalvy J. Distribution of microplastics present in a stream that receives discharge from wastewater treatment plants. Environ Pollut 2022; 314:120299. [PMID: 36181936 DOI: 10.1016/j.envpol.2022.120299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 09/22/2022] [Accepted: 09/25/2022] [Indexed: 06/16/2023]
Abstract
The presence of microplastics (MPs) in freshwater systems that receive discharge of urban effluent implies a great environmental impact. In order to be able to generate proposals that solve this problem, it is necessary to know in detail the contributions of different MPs sources. The aim of this work was to study the contribution of urban sewage discharge to MPs pollution in a stream that runs through a medium-sized city. The spatial distribution of MPs with sizes between 100 μm and 1.5 mm present in surface water was measured and their characteristics, dimensions, shapes and identification were determined. Physical-chemical parameters of the stream water were measured, and a decrease in water quality was found due to wastewater treatment plants. The main source of MPs was effluent from the plants (97% of the total MPs), while the rest came from storm drains and discharge of tributaries. The maximum concentration of MPs found was around 72,000 MP/L (equivalent to 53 million MPs/s), at a point after discharge from both plants. Around 70% of MPs correspond to microfibers with a mean length of around 300 μm and a mean width of around 15 μm, and they are mainly polyethylene fibers. The remaining 30% of MPs are particles with lengths of around 140 μm. The transport of MPs between a point located after discharge of the plants and another point located about 3 km further on was studied, and no significant variation was found in the concentration of MPs. Electrical conductivity was used as a conservative tracer of MPs concentration. This work presents for the first time a detailed analysis of different contributions of MPs to a freshwater system in South America, which receives discharge of wastewater treatment plants, evidencing its important role in pollution.
Collapse
Affiliation(s)
- S Montecinos
- IFIMAT, Facultad de Ciencias Exactas, Universidad Nacional del Centro de la Provincia de Buenos Aires, Pinto 399, 7000, Tandil, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas CONICET, Av. Rivadavia, 1917, C1033AAJ, Buenos Aires, Argentina; CIFICEN (UNCPBA-CICPBA-CONICET), Pinto 399, 7000, Tandil, Argentina.
| | - M Gil
- IFIMAT, Facultad de Ciencias Exactas, Universidad Nacional del Centro de la Provincia de Buenos Aires, Pinto 399, 7000, Tandil, Argentina
| | - S Tognana
- IFIMAT, Facultad de Ciencias Exactas, Universidad Nacional del Centro de la Provincia de Buenos Aires, Pinto 399, 7000, Tandil, Argentina; CIFICEN (UNCPBA-CICPBA-CONICET), Pinto 399, 7000, Tandil, Argentina; Comisión de Investigaciones Científicas de la Provincia de Bs. As., Calle 526 Entre 10 y 11, 1900, La Plata, Argentina
| | - W Salgueiro
- IFIMAT, Facultad de Ciencias Exactas, Universidad Nacional del Centro de la Provincia de Buenos Aires, Pinto 399, 7000, Tandil, Argentina; CIFICEN (UNCPBA-CICPBA-CONICET), Pinto 399, 7000, Tandil, Argentina; Comisión de Investigaciones Científicas de la Provincia de Bs. As., Calle 526 Entre 10 y 11, 1900, La Plata, Argentina
| | - J Amalvy
- Comisión de Investigaciones Científicas de la Provincia de Bs. As., Calle 526 Entre 10 y 11, 1900, La Plata, Argentina; CITEMA (UTN-CICPBA) 60 y 124, 1900, La Plata, Argentina
| |
Collapse
|
6
|
Ferreira Guerra J, Pina J, Andrade V, Medeiros M, Guimaraes T, Gil M, Cunha J, Silva P, Pinheiro L. BCG installations may mimic prostate cancer on multiparametric magnetic resonance. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02473-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
7
|
Ferreira Guerra J, Pina J, Andrade V, Medeiros M, Fernandes F, Guimarães T, Gil M, Cunha J, Silva P, Pinheiro L. What is the benefit of performing saturation prostate biopsies in addition to multiparametric magnetic resonance imaging targeted biopsies? EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02486-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
8
|
Corcoy M, Romero I, Lòpez V, Gil M, Centeno C, Sadurni M, Carazo J, Rodriguez C, Aguilera L. Effectiveness and safety of a Crossfit® adapted training on improving functional capacity in a prehabilitation program for oncologic patients undergoing major surgery. Clin Nutr ESPEN 2022. [DOI: 10.1016/j.clnesp.2022.06.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Mendes Andrade V, Silva P, Cunha J, Gil M, Guerra J, Medeiros M, Guimarães T, Calais F, Severo L, Campos Pinheiro L. Peyronie’s disease: Differences in male and female personal experience. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02058-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
10
|
Galleani C, Bautista-Villanueva S, Piorno I, Moya B, Mielgo R, Gil M, Crespo JF. Remdesivir-induced non-immediate cutaneous hypersensitivity reaction. J Investig Allergol Clin Immunol 2022:0. [PMID: 35834314 DOI: 10.18176/jiaci.0844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C Galleani
- Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - I Piorno
- Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - B Moya
- Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - R Mielgo
- Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M Gil
- Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J F Crespo
- Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
11
|
Plazas JG, Arias-Martinez A, Lecumberri A, Martínez de Castro E, Custodio A, Cano JM, Hernandez R, Montes AF, Macias I, Pieras-Lopez A, Diez M, Visa L, Tocino RV, Lago NM, Limón ML, Gil M, Pimentel P, Mangas M, Granja M, Carnicero AM, Pérez CH, Gonzalez LG, Jimenez-Fonseca P, Carmona-Bayonas A. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. ESMO Open 2022; 7:100514. [PMID: 35714478 PMCID: PMC9271495 DOI: 10.1016/j.esmoop.2022.100514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2022] [Revised: 05/09/2022] [Accepted: 05/18/2022] [Indexed: 11/17/2022] Open
Abstract
Background Recommendations for research articles include the use of the term sex when reporting biological factors and gender for identities or psychosocial or cultural factors. There is an increasing awareness of incorporating the effect of sex and gender on cancer outcomes. Thus, these types of analyses for advanced gastroesophageal adenocarcinoma are relevant. Patients and methods Patients with advanced gastroesophageal adenocarcinoma from the Spanish AGAMENON-SEOM registry treated with first-line combination chemotherapy were selected. Epidemiology, characteristics of the disease, treatment selection, and results were examined according to sex. Results This analysis included 3274 advanced gastroesophageal adenocarcinoma patients treated with combination chemotherapy between 2008 and 2021: 2313 (70.7%) men and 961 (29.3%) women. Tumors in females were more frequently HER2-negative (67.8% versus 60.8%; P < 0.0001), grade 3 (45.4% versus 36.8%; P < 0.001), diffuse (43.3% versus 26.5%; P < 0.0001), and signet ring cell histology (40.5 versus 23.9%; P < 0.0001). Peritoneal spread was more common in women (58.6% versus 38.9%; P < 0.0001), while liver burden was lower (58.9% versus 71.1%; P < 0.0001). There were no significant differences in treatment recommendation. Treatment doses, density, and duration were comparable between sexes. Women experienced more diarrhea (46% versus 37%; P < 0.0001), neutropenia (51% versus 43%; P < 0.0001), and anemia (62% versus 57%; P < 0.0001). After a median 59.6-month follow-up [95% confidence interval (CI) 54.5-70.8], there were no statistically significant differences between the sexes in progression-free survival [6.21 months (95% CI 5.8-6.5 months) versus 6.08 months (95% CI 5.8-6.3 months); log-rank test, χ2 = 0.1, 1 df, P = 0.8] or in overall survival [10.6 months (95% CI 9.8-11.1 months) versus 10.9 months (95% CI 10.4-11.4 months); log-rank test: χ2 = 0.6, 1 df, P = 0.5]. Conclusion This sex analysis of patients with advanced gastroesophageal adenocarcinoma from the AGAMENON-SEOM registry receiving first-line polychemotherapy found no differences in survival. Although women had worse prognostic histopathology, metastatic disease pattern, and greater toxicity, treatment allocation and compliance were equivalent. Sex and gender are determinants of health inequalities and may affect treatments, tolerability, and therapeutic outcomes. According to sex, subtle biological and clinical differences exist in advanced gastroesophageal adenocarcinoma. Women with advanced gastroesophageal adenocarcinoma experience greater toxicity with therapeutic results comparable with men. Stratification and analysis by sex in studies of gastroesophageal adenocarcinoma should be considered.
Collapse
Affiliation(s)
- J Gallego Plazas
- Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain.
| | - A Arias-Martinez
- Pharmacy Department, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain
| | - A Lecumberri
- Medical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain
| | - E Martínez de Castro
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - A Custodio
- Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain
| | - J M Cano
- Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - R Hernandez
- Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - A F Montes
- Medical Oncology Department, Complejo Hospitalario de Ourense, Ourense, Spain
| | - I Macias
- Medical Oncology Department, Hospital Universitario Parc Taulí, Sabadell, Spain
| | - A Pieras-Lopez
- Pharmacy Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
| | - M Diez
- Medical Oncology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - L Visa
- Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain
| | - R V Tocino
- Medical Oncology Department, Complejo Asistencial Universitario de Salamanca - ISBAL, Salamanca, Spain
| | - N Martínez Lago
- Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, Coruña, Spain
| | - M L Limón
- Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - M Gil
- Medical Oncology Department, Hospital General Universitario de Valencia - Ciberonc CB16/12/0035, Valencia, Spain
| | - P Pimentel
- Medical Oncology Department, Hospital Santa Lucía, Cartagena, Spain
| | - M Mangas
- Medical Oncology Department, Hospital Galdakao-Usansolo, Galdakao-Usansolo, Spain
| | - M Granja
- Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - A M Carnicero
- Medical Oncology Department, Hospital San Pedro, Logroño, Spain
| | - C Hernández Pérez
- Medical Oncology Department, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain
| | - L G Gonzalez
- Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain
| | - P Jimenez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
| | - A Carmona-Bayonas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain
| |
Collapse
|
12
|
Mendes Andrade V, Guimarães T, Medeiros M, Guerra J, Gil M, Cunha J, Silva P, Pina J, Campos Pinheiro L. Will be the systematic biopsy useful when added to the MRI/TRUS fusion biopsy? EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)00665-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
13
|
Guimaraes T, Medeiros M, Andrade V, Guerra J, Gil M, Bernardino R, Pinheiro H, Pina J, Campos Pinheiro L. Kidney retained fragmented double J stent - a challenging problem for urologist with potential medico-legal serious implication. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)00093-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
14
|
Guimaraes T, Gil M, Pinheiro H, Pina J, Cabrita Carneiro J, Pinto Marques H, Campos Pinheiro L. Challenging robotic right nephrectomy, retroperitoneal lymph nodes dissection and inferior vena cava tumor thrombectomy - a surgical video report. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)00113-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Gil M, Flores I, Seguro A, Campos F, Iborra M. Breast VMAT optimization using uniform equivalent dose (EUD) objectives at organs at risk. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00339-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
16
|
Sonpavde G, Koshkin V, Hwang C, Mellado B, Tomlinson G, Shimura M, Chisamore M, Gil M, Loriot Y. A phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC). EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03206-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
17
|
Kabalkin Y, Gil M, Lifshitz E, Moav A, Kabessa M, Jaber S, Broder EE, Bentov Y, Assaf B, Solnica A, Walfisch A, Holzer H, Klement AH. O-225 Effects of SARS-Corona virus 2 on IVF treatment parameters: A cohort study of post COVID-19 patients. Hum Reprod 2021. [DOI: 10.1093/humrep/deab128.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does recovery from SARS–Corona virus 2 (SARS–CoV-2) infection negatively effect IVF cycle parameters?
Summary answer
Female IVF treatment parameters were comparable to the pre-Covid-19 infection cycle performance. Sperm concentration and motility demonstrated lower mean counts following Covid-19 infection.
What is known already
Corona-virus disease-19 (Covid-19) is a global pandemic caused by SARS–Corona virus 2 (SARS–CoV-2). The virus primarily affects the respiratory system, but other systemic and immune mediated effects have been reported. The spikes of SARS-CoV-2 have strong affinity for the Angiotensin converting enzyme (ACE) 2 receptor, leading to an increased Angiotensin II (Ang II) mediated pro-inflammatory response. ACE2 receptors exist in the human reproductive tract (more in males) and pose a regulatory role together with Ang II. So far, reports have been inconsistent regarding testicular effects. Other implications involving fertility and fertility treatment post infection are scarce.
Study design, size, duration
In this retrospective cohort study, IVF cycle performance was compared before and after Corona-virus disease-19. Patients were included only in cases where an IVF cycle was initiated within 3 months of Covid-19 recovery, between March 2020-December 2020.
Participants/materials, setting, methods
The study was conducted in a University affiliated IVF unit. Post Covid- 19 cycle parameters were compared to previous cycles of the same individual prior to infection. If previous cycles were not available, parameters were compared to non-exposed patients of same age, same treatment and identical indication. Sperm concentration and motility were compared before and after infection. Non exposure was defined by a lack of past Covid-19 diagnosis and a negative PCR throughout the treatment.
Main results and the role of chance
All together, including the matched cycles, we compared 40 cycles which started within 3 months of recovery: 26 fresh stimulation cycles and 14 frozen thawed transfer cycles. In 28 of these cycles the patient could serve as its own control. Mean age for the female partner was 33.2 years ±6.5 years. Eight male partners presented post infection and provided fresh samples for a cycle involving fertilization. We compared stimulation parameters including maximal Estradiol level, stimulation length, FSH dosage, number of oocytes retrieved, fertilization rates, number of embryos created, high quality embryo number and endometrial thickness. All of these were comparable to non-exposed cycles (generalized estimating equations, p values >0.1). No complications were recorded, specifically no thromboembolic events or respiratory complications. A total of 8 patients conceived: 1 was a chemical pregnancy, 1 extra-uterine pregnancy, 3 miscarriages and 3 ongoing, of those 1 was complicated by early bleeding. Male sperm analyses showed a trend towards lower post disease parameters, not reaching a statistical significance: 23mil/ml compared to 13.6 and 20.7% progressive motility compared to 12.3% (p values 0.09 and 0.17, respectively).
Limitations, reasons for caution
Current results are based on a small sample size, still insufficient for deducing definite conclusions or guidelines. Pregnancy outcome following IVF treatment in Covid-19 recoverees should further be studied. By the time of the conference, the number of cases is expected to be significantly higher.
Wider implications of the findings
This study provides preliminary data regarding the effects of SARS-COV-2 infection on IVF treatment outcomes. Despite the small sample size, treatment parameters seem unaffected, however, sperm performance seems to be compromised. Health policy and patients’ decisions regarding whether or not to postpone IVF procedures necessitates additional data.
Trial registration number
Not applicable - retrospective
Collapse
Affiliation(s)
- Y Kabalkin
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - M Gil
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - E Lifshitz
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - A Moav
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - M Kabessa
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - S Jaber
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | | | - Y Bentov
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - B Assaf
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - A Solnica
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - A Walfisch
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - H Holzer
- Hadassah Medical Centre, Ob Gyn, Jerusalem, Israel
| | - A. Hershko Klement
- The Hebrew University Medical school, The IVF unit- Hadassah Mt. Scopus, Kiryat Ono, Israel
| |
Collapse
|
18
|
Mazzucchelli R, Rodriguez-Martin S, García-Vadillo A, Gil M, Rodríguez-Miguel A, Barreira-Hernández D, García-Lledó A, De Abajo F. OP0234 RISK OF ACUTE MYOCARDIAL INFARCTION AMONG NEW USERS OF CHONDROITIN SULPHATE: A NESTED CASE-CONTROL STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:There is some evidence from epidemiological studies suggesting that CS and glucosamine could play a role in cardiovascular disease (CVD) prevention (1-4).Studies to date have included prevalent users, therefore a bias that overestimates protection cannot be excluded.Objectives:To test the hypothesis that chondroitin sulphate (CS) or glucosamine reduce the risk of acute myocardial infarction (AMI).Methods:Case-control study nested in a primary cohort composed of patients aged 40 to 99 years, with at least one year of follow-up in the BIFAP database during the 2002-2015 study period. From this cohort of patients, we identified incident cases of AMI and randomly selected five controls per case, matched by exact age, gender, and index date. Adjusted odds ratios (AOR) and their corresponding 95% confidence interval (CI)) were calculated through a conditional logistic regression. Only new users of CS or glucosamine were considered.Results:A total of 23,585 incident cases of AMI and 117,405 controls were included. The mean age was 67.0 (SD 13.4) years and 71.75% were male, in both groups. 558 (2.37%) cases and 3,082 (2.62%) controls used or had used CS. The current use of CS was associated with a lower risk of AMI (AOR 0.57; 95%CI: 0.46–0.72) and disappeared after discontinuation (recent and past users). The reduced risk among current users was observed in both short-term (<365 days AOR 0.58; 95%CI: 0.45-0.75) and long-term users (>364 days AOR 0.56; 95%CI 0.36-0.87), in both sexes (men, AOR=0.52; 95%CI:0.38-0.70; women, AOR=0.65; 95%CI: 0.46-0.91), in individuals over or under 70 years of age (AOR=0.54; 95%CI:0.38-0.77, and AOR=0.61; 95%CI:0.45-0.82, respectively) and in individuals at intermediate (AOR=0.65; 95%CI:0.48-0.91) and high cardiovascular risk (AOR=0.48;95%CI:0.27-0.83), but not in those at low risk (AOR=1.11; 95%CI:0.48-2.56). In contrast, the current use of glucosamine was not associated with either increased or decreased risk of AMI (AOR= 0.86; CI95% 0.66-1.08)Conclusion:Our results support a cardioprotective effect of CS, while no effect was observed with glucosamine. The highest protection was found among subgroups at higher cardiovascular risk.References:[1]Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019;365(Journal Article):l1628.[2]de Abajo FJ, Gil MJ, Garcia Poza P, Bryant V, Oliva B, Timoner J, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. PharmacoepidemiolDrug Saf. 2014;23(11):1128–38.[3]Li Z-H, Gao X, Chung VC, Zhong W-F, Fu Q, Lv Y-B, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. Ann Rheum Dis. 2020 Apr 6;annrheumdis-2020-217176.[4]King DE, Xiang J. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. 2020 Dec;33(6):842–7.Disclosure of Interests:Ramón Mazzucchelli Speakers bureau: UCB, Lilly, Grant/research support from: Pfizer, Roche, Amgen, Sara Rodriguez-Martin: None declared, Alberto García-Vadillo: None declared, Miguel Gil: None declared, Antonio Rodríguez-Miguel: None declared, Diana Barreira-Hernández: None declared, Alberto García-Lledó: None declared, Francisco de Abajo: None declared
Collapse
|
19
|
Mazzucchelli R, Rodríguez-Martín S, García-Vadillo A, Crespí-Villarías N, Gil M, Rodriguez-Miguel A, Barreira D, Garcia-Lledó A, de Abajo FJ. Risk of acute myocardial infarction among new users of bisphosphonates: a nested case-control study. Osteoporos Int 2020; 31:2403-2412. [PMID: 32662036 DOI: 10.1007/s00198-020-05538-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Accepted: 07/07/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To test the hypothesis that bisphosphonates reduce AMI risk among new users and to assess whether the effect depends on the duration of treatment. METHODS Case-control study nested in a primary cohort composed of patients aged 40 to 99 years, with at least 1-year registry in the BIFAP database throughout the study period 2002-2015. Out of this cohort, incident AMI cases were identified and five controls per case were randomly selected, matched by exact age, sex, and index date. The association of AMI with current, recent and past use of bisphosphonates was assessed by computing adjusted odds ratios (AOR) and their corresponding 95% confidence interval (CI) through an unconditional logistic regression. Only initiators of bisphosphonates were considered. RESULTS A total of 23,590 cases of AMI and 117,612 controls were included. The mean age was 66.8 (SD 13.4) years, and 72.52% was male, in both groups. About 276 (1.17%) cases and 1458 (1.24%) controls were current users of bisphosphonates yielding an AOR of 0.98 (95% CI 0.854-1.14). Recent and past use were not associated with a reduced risk, either, nor was it found a reduction with treatment duration (AOR less than 1 year = 0.92; 95% CI 0.73-1.15; AOR more than 1 year = 1.03; 95% CI 0.86-1.23). Stratified analysis by age, sex and background cardiovascular risk did not show an effect modification by these variables. CONCLUSION The results do not support a cardioprotective effect of bisphosphonates regardless of the duration of treatment, age, sex or background cardiovascular risk. However, a small protective effect could have been masked if patients with osteoporosis have had a background higher risk of AMI.
Collapse
Affiliation(s)
- R Mazzucchelli
- Rheumatology Unit, Hospital Universitario Fundación Alcorcón, 28922, Alcorcón, Madrid, Spain
| | - S Rodríguez-Martín
- Clinical Pharmacology Unit, Hospital Universitario Príncipe de Asturias, 28805, Alcalá de Henares, Madrid, Spain
- Department of Biomedical Sciences (Pharmacology), Facultad de Medicina y Ciencias de la Salud, Universidad de Alcala (IRYCIS), 28805, Alcalá de Henares, Madrid, Spain
| | - A García-Vadillo
- Rheumatology Department, Hospital Universitario La Princesa, 28006, Madrid, Madrid, Spain
| | | | - M Gil
- Division of Pharmacoepidemiology and Pharmacovigilance of the Spanish Agency on Medicines and Medical Devices (AEMPS), 28022, Madrid, Spain
| | - A Rodriguez-Miguel
- Clinical Pharmacology Unit, Hospital Universitario Príncipe de Asturias, 28805, Alcalá de Henares, Madrid, Spain
- Department of Biomedical Sciences (Pharmacology), Facultad de Medicina y Ciencias de la Salud, Universidad de Alcala (IRYCIS), 28805, Alcalá de Henares, Madrid, Spain
| | - D Barreira
- Clinical Pharmacology Unit, Hospital Universitario Príncipe de Asturias, 28805, Alcalá de Henares, Madrid, Spain
- Department of Biomedical Sciences (Pharmacology), Facultad de Medicina y Ciencias de la Salud, Universidad de Alcala (IRYCIS), 28805, Alcalá de Henares, Madrid, Spain
| | - A Garcia-Lledó
- Department of Cardiology, Hospital Universitario Príncipe de Asturias, 28805, Alcalá de Henares, Madrid, Spain
- Department of Medicine, Universidad de Alcalá, 28805, Alcalá de Henares, Madrid, Spain
| | - F J de Abajo
- Clinical Pharmacology Unit, Hospital Universitario Príncipe de Asturias, 28805, Alcalá de Henares, Madrid, Spain.
- Department of Biomedical Sciences (Pharmacology), Facultad de Medicina y Ciencias de la Salud, Universidad de Alcala (IRYCIS), 28805, Alcalá de Henares, Madrid, Spain.
| |
Collapse
|
20
|
Ozcariz E, Rojo G, Gil M, Guardiola M, Amigo N, Ribalta J. Characterization of the metabolomic profile by 1H-nuclear magnetic resonance spectroscopy in the DI@BET.ES study. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Gil M, Rojo G, Ozcariz E, Guardiola M, Amigo N, Masana L, Ribalta J. Exploring lipoprotein patterns in DI@BET.ES study. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
Rodríguez-Carrio J, Alperi-López M, López P, Gil M, Amigo N, Pérez-Álvarez Á, Benavente L, Suárez A. GlycA as a biomarker of inflammation and subclinical atherosclerosis in very early rheumatoid arthritis. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Bernardino R, Gil M, Andrade V, Severo L, Alves M, Papoila AL, Campos Pinheiro L. What has changed during the state of emergency due to COVID-19 on an Academic Urology Department of a Tertiary Hospital in Portugal. Actas Urol Esp 2020; 44:604-610. [PMID: 32843150 PMCID: PMC7381920 DOI: 10.1016/j.acuro.2020.06.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2020] [Accepted: 06/30/2020] [Indexed: 12/13/2022]
Abstract
Objetivo Comparar la actividad del Servicio de Urología de un Hospital Universitario Portugués durante el estado de alarma y el periodo equivalente del año anterior. Comparamos el número de consultas electivas y pruebas diagnósticas urológicas, el número y el tipo de cirugías electivas, así como las características demográficas de los pacientes y las principales causas de ingreso al Servicio de Urgencias (SU) de Urología durante los dos periodos mencionados. Materiales y métodos Los datos de 691 pacientes que acudieron a urgencias desde el 18 de marzo de 2020 hasta el 2 de mayo de 2020 -y del mismo periodo del año anterior- se recogieron del software medico institucional. Los datos recopilados fueron edad, sexo, fecha de visita al servicio de urgencias, derivación desde otros hospitales, color del triaje, causa del ingreso, diagnóstico al alta y la necesidad de cirugía de urgencia u hospitalización. Con la intención de identificar las asociaciones entre las variables demográficas y clínicas con el hecho de haber sido sometido a una cirugía de urgencia (variable), se aplicaron modelos de regresión logística. Resultados El análisis multivariante mostró asociación entre el sexo del paciente con el hecho de ser sometido a una cirugía, con una disminución del 65,6% en las probabilidades para el género masculino. El periodo (COVID versus sin-COVID) no mostró una asociación significativa con la cirugía. Conclusión Nuestro departamento experimentó una reducción importante en la actividad. También observamos una reducción de las causas urgentes para acudir a los servicios de urgencias considerados menos graves. El porcentaje de casos que requirieron cirugía de urgencia y hospitalización fue mayor durante el periodo COVID.
Collapse
Affiliation(s)
- R Bernardino
- Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal.
| | - M Gil
- Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal
| | - V Andrade
- Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal
| | - L Severo
- Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal
| | - M Alves
- Epidemiology and Statistics Unit, Research Center, Central Lisbon Hospital Center, Lisbon, Portugal
| | - A L Papoila
- Epidemiology and Statistics Unit, Research Center, Central Lisbon Hospital Center, Lisbon, Portugal
| | - L Campos Pinheiro
- Urology Department, Central Lisbon Hospital Center, Lisbon, Portugal
| |
Collapse
|
24
|
Cabeza M, Gambardella V, Alarcón L, Herrera G, Garzón-Lloría Z, Martínez-Ciarpaglini C, Carbonell-Asíns J, Villagrasa R, Navarro P, Gil M, Richart P, López F, Fernández M, Huerta M, Cervantes A, Castillo J, Fleitas T. 1480P M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
25
|
Gil M, Garcia M, Aguiar P. Factors that influence the response time in STEMI patients in Lisbon 2017. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.1159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
The success of the ST-segment elevation myocardial infarction (STEMI) approach is based on early diagnosis and on the institution of timely reperfusion therapy, with response times remaining variable. The objective of this study was to determine which factors influenced the response time to patients with STEMI until the treatment with coronary reperfusion from the prehospital service or the emergency room in three hospitals in the greater Lisbon area in 2017. An epidemiological, cross-sectional, retrospective, descriptive study with an analytical component was performed, with data from the National Institute of Medical Emergency (INEM) and clinical trials of patients. Patients who were not referred to these hospitals were excluded. Univariate statistical analysis was performed, as well as c2 tests, t-student and logistic regression model (r < 0.05). The population included 95 patients, the majority being male (67.4%), and with a mean age of 63.8 years. 61.1% were hypertensive and the majority (87.4%) had no signs of previous heart failure. The mean door-to-balloon time was 159 minutes, with 57.4% showing time greater than 120 minutes. In patients in whom the INEM Coronary Greenway was activated, mean door-to-balloon time was 99 minutes. Diagnostic, symptom-admission and transport times showed a statistically significant association with the door-to-balloon time in the bivariate analysis. The times are fulfilled in the prehospital service, but in the hospital, services can be improved through the early accomplishment of electrocardiogram and the optimization of interhospital transport.
Key messages
Reducing ECG time and inter-hospital transport time improves STEMI response and outcome. Time is muscle is the main message for de concern of identifying influence factors of STEMI response time.
Collapse
Affiliation(s)
- M Gil
- ACES Loures-Odivelas, Santo António dos Cavaleiros, Portugal
| | - M Garcia
- ACES Loures-Odivelas, Santo António dos Cavaleiros, Portugal
| | - P Aguiar
- ACES Loures-Odivelas, Santo António dos Cavaleiros, Portugal
| |
Collapse
|
26
|
Gil M, Rodríguez DR, Fuente ECDL, Huertas RM, Sanz L, Pozas J, Ballesteros P, Fernandez VA, Perez JC, Vaz M, Delgado MV, Fuentes R, Olmos VP, Puertas PR, Garrote MR, Monteagudo RF, Carrato A, Longo F, Domingo JS. P-187 Impact on survival of local complications in pancreatic cancer: Experience at the Ramón y Cajal University Hospital (HURyC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
27
|
Mazzucchelli R, Rodriguez-Martin S, García-Vadillo A, García-Lledó A, Gil M, De Abajo F. SAT0446 RISK OF ACUTE MYOCARDIAL INFARCTION (AMI) AMONG NEW USERS OF BISPHOSPHONATES: A NESTED CASE-CONTROL STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Evidence suggest that bisphosphonates (BF) may inhibit atherosclerosis and vascular calcification. In several small-scale clinical trials, BF improved some intermediate targets of atherosclerosis. Observational studies found a lower risk of Acute Myocardial Infarction (AMI) or stroke among BF users compared to non-users. While this epidemiological evidence suggests that BF may protect against cardiovascular events a “prevalent user bias” cannot be excluded.Objectives:To analyze the hypothesis that BF reduce de risk of AMI in new users and assess whether the effect depends on the duration of treatment.Methods:Case-control study nested in a primary cohort composed of patients aged 40 to 99 years, with at least one year of follow-up in the BIFAP database during the 2002-2015 study period. From this cohort of patients, we identified incident cases of AMI and randomly selected five controls per case, matched by exact age, gender, and index date. Adjusted odds ratios (AOR) and their corresponding 95% confidence interval (CI) were calculated through an unconditional logistic regression. Only new users of BF were considered.Results:A total of 23,590 cases of IAM and 117,612 controls were included. The mean age was 66.8 (SD 13.4) years and 72.52% were male, in both groups. 584 (2,47%) cases and 2,892 (2.46%) controls used or had used some bisphosphonate. The use of BF was not associated with a lower risk of IAM (AOR 0.97; 95%CI: 0.84–1.13). Nor was it associated with the duration of treatment (AOR less than 1 year = 0.91; 95%CI: 0.72-1.15);AOR more than 1 year= 1.01; 95%CI: 0.84-1.21). The stratified analysis by age and sex also did not show either a protective effect of BF. Detailed results by BF type are shown in the following table:Cases (%)Controls (%)Non-adjusted ORAdjusted ORN=23590N=117612(95% CI)(95% CI)BisphosphonatesNon users23006 (97.52)114720 (97.54)1 (Ref.)1 (Ref.)Current276 (1.17)1458 (1.24)0.93 (0.81-1.06)0.97 (0.84-1.13)Recent109 (0.46)478 (0.41)1.13 (0.92-1.40)1.11 (0.89-1.40)Past199 (0.84)956 (0.81)1.04 (0.89-1.21)1.01 (0.86-1.20)Alendronic acidNon users23338 (98.93)116421 (98.99)1 (Ref.)1 (Ref.)Current88 (0.37)469 (0.40)0.91 (0.72-1.15)0.97 (0.76-1.24)Recent46 (0.19)201 (0.17)1.17 (0.84-1.61)1.18 (0.83-1.66)Past118 (0.50)521 (0.44)1.12 (0.91-1.37)1.13 (0.91-1.40)Alendronic acid+VitDNon users23509 (99.66)117155 (99.61)1 (Ref.)1 (Ref.)Current34 (0.14)207 (0.18)0.81 (0.56-1.17)0.89 (0.60-1.31)Recent15 (0.06)77 (0.07)0.94 (0.54-1.63)0.71 (0.40-1.29)Past32 (0.14)173 (0.15)0.92 (0.63-1.35)0.83 (0.56-1.25)Alendronic acid (all)Non users23274 (98.66)116057 (98.68)1 (Ref.)1 (Ref.)Current122 (0.52)671 (0.57)0.89 (0.73-1.08)0.95 (0.77-1.18)Recent58 (0.25)261 (0.22)1.11 (0.83-1.48)1.03 (0.76-1.39)Past136 (0.58)623 (0.53)1.08 (0.89-1.31)1.05 (0.86-1.29)Ibandronic acidNon users23504 (99.64)117174 (99.63)1 (Ref.)1 (Ref.)Current41 (0.17)216 (0.18)0.96 (0.68-1.34)1.00 (0.70-1.42)Recent18 (0.08)69 (0.06)1.24 (0.74-2.09)1.38 (0.80-2.36)Past27 (0.11)153 (0.13)0.87 (0.57-1.31)0.88 (0.57-1.35)Risedronic acidNon users23355 (99.00)116446 (99.01)1 (Ref.)1 (Ref.)Current102 (0.43)527 (0.45)0.95 (0.76-1.18)0.99 (0.79-1.25)Recent47 (0.20)186 (0.16)1.27 (0.92-1.75)1.17 (0.83-1.66)Past86 (0.36)453 (0.39)0.94 (0.75-1.19)0.93 (0.72-1.19)Conclusion:Our results do not support a cardioprotective effect of BF, regardless of the duration of treatment, age, sex or background cardiovascular risk.Disclosure of Interests:None declared
Collapse
|
28
|
Salamero MC, Te García IR, Arroyo A, Pardo B, Gil M, Piulats J, Pla H, Fina C, Ginesta MPB, Angelats L, Falgas EF, Lecuona CE, Mosquera JJG, Román SM, Carballas E, Hernandez J, Esteve A, Romeo M. The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Rodríguez-Borjabad C, Ibarretxe D, Feliu A, Ferré R, Rosell L, Gil M, Masana L, Plana N. Significant Impact Of A Lifestyle Educational Program On Children With Genetically Driven Hypercholesterolemia. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Garcia EO, Gil M, Rodríguez D, Samino S, Amigó N. Lipidic Silhouette: A New Graphical Model To Study Lipoprotein Metabolism Disturbances. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Gandhi S, Gil M, Khoury T, Takabe K, Puzanov I, Gelman I, D'Assoro A, Opyrchal M. Abstract P2-06-17: A novel interaction of AURKA with MAPK pathway in breast cancer cells as a potential therapeutic target. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-06-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aurora A (AURKA) is a mitotic kinase responsible for centrosome segregation and mitotic spindle formation. In normal cells, expression of AURKA is highly regulated and is predominantly restricted to G2/M phases of the cell cycle. Unlike healthy cells, cancer cells overexpress AURKA through all phases of the cell cycle resulting in the acquisition of alternate non-mitotic functions. Little is known about cellular functions regulated by AURKA and its interaction with other signaling molecules. Here, we report a novel interaction between AURKA and the mitogen-activated protein kinase (MAPK) pathway at the level of MEK1 in breast cancer cells. This interaction may serve as a novel target as well as demonstrate by an additive cytotoxic effect of AURKA- and MEK1/2-specific inhibitors against estrogen positive (ER+) and triple negative breast cancer (TNBC) cells.
Results: We show that treatment of ER+ HER2- MCF-7, ER- HER2+ SKBR3 and ER- HER2- BT549 cells with AURKA specific inhibitors alisertib, MK8745 and Aurora A Inhibitor I resulted in over 2-fold increase in relative levels of poMEK1/2 and poERK1/2 compared to untreated controls. The activation of the MAPK pathway was rapid with changes seen within 5 min after treatment with AURKA inhibitors and was sustained for at least 48 hours. Treatment with the pan RAF inhibitor TAK-632 did not diminish alisertib-induced poERK and poMEK1/2. Alternatively, treatment with the MEK1/2 specific inhibitor PD0325901 completely abrogated alisertib-induced phosphorylation of MEK1/2 and ERK1/2. In situ proximity ligation and pull down assays demonstrated AURKA and MEK1/2 direct interaction. In vitro kinase assay showed direct phosphorylation of MEK1 by AURKA. Combined treatment of alisertib and PD0325901 in vitro revealed significant additive cytotoxic effect in MCF-7 and BT549 cells when compared to either agent used alone (p< 0.008 and p<0.011; p <0.04 and p<0.028) with early trend toward significance in survival in a BT549 xenograft breast cancer in vivo model.
Conclusions: Our data shows a novel AURKA-MEK1 interaction in breast cancer cells. In depth in vivo analysis is ongoing. The results reveal a promising new strategy for the treatment TNBC patients using a combination of AURKA and MEK1/2 inhibitors.
Citation Format: Gandhi S, Gil M, Khoury T, Takabe K, Puzanov I, Gelman I, D'Assoro A, Opyrchal M. A novel interaction of AURKA with MAPK pathway in breast cancer cells as a potential therapeutic target [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-06-17.
Collapse
Affiliation(s)
- S Gandhi
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - M Gil
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - T Khoury
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - K Takabe
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - I Puzanov
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - I Gelman
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - A D'Assoro
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| | - M Opyrchal
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN
| |
Collapse
|
32
|
Fernandez-Gonzalez S, Falo Zamora C, Nuñez D, Vethencourt A, Pla MJ, Soler T, Guma A, Perez X, Gil M, Ponce J, Garcia A. Abstract P6-09-04: Predictive factors for considering to avoid axillar lymphadenectomy in selected node positive breast cancer patients after neoadjuvant chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-09-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
To perform a systematic axillar lymphadenectomy (ALND) in clinical node positive (N+) patients after neoadjuvant chemotherapy (NACT) is currently under discussion. We aimed to study which factors are related to a pathological complete axillar response (ypN0) after NACT in order to select which patients could benefit from a sentinel lymph node biopsy without interfering with survival.
Material and methods
N+ patients who underwent ALND after NACT between June 2008 and December 2016 were retrospectively analyzed. Clinical features, molecular and histological factors, recurrence and specific mortality rates were compared between patients achieving a complete pathological axillary response vs not (ypN0 vs ypN+).
Results
345 N+ patients were reviewed. After NACT, 137 (39.6%) become ypN0[CF1] , 9 (2.6%) ypN1 mic, 113 (32.7%) ypN1, 60 (17.3%) ypN2 and 22 (6.4%) N3. Univariate analysis results regarding the predictive factors for ypN0 are detailed in [table 1]. Multivariate analyses showed molecular subtype (TN and Her2+) and clinical response as independent predictors of ypN0 [table 2]. After a mean follow-up of 58 months, overall survival was statistically superior in ypN0 vs ypN1 (p= 0.001).
Table 1.Predictive factors for ypN0 YpN0 (n = 137)YpN+ (n = 208)pAge (mean, years)58.3 ± 13.2758.59 ± 12.340.799BMI (mean)27.8±5.4927.8±5.360.973Dosis of QT (median)(%) 0.575IIA6 (31.6)13 (68.4) IIB71 (39.3)110 (60.8) IIIA28 (36.8)48 (63.2) IIIB24 (43.6)31 (56.4) IIIC7 (58.3)5 (41.7) Radiological image(%) 0.930Nodule77 (38.1)125 (61.9) Non-mass distortion10 (43.5)13 (56.5) Radiological size (median)32 (0-115)29 (0-130)0.246Suspicious a-LN by US(%) 0.486130 (30.9)37 (24.3) 25 (5.2)14 (9.2) >257 (58.8)91 (59.9) Histological subtype(%) 0.093Invasive Ductal Carcinoma133 (40.9)192 (59.1) Invasive Lobular Carcinoma2 (20)8 (80) Others2 (22.2)7 (78.8) Nottingham grade(%) <0.001G11 (6.2)15 (93.8) G244 (28.6)110 (71.4) G386 (53.4)75 (46.6) Molecular-like subtype(%) <0.001Luminal A-like2 (5.3)36 (94.7) Luminal B-like (Her2 -)21(18.1)95 (81.9) Luminal B-like (Her2 +)40 (63.5)23 (36.5) HER-2 enriched (non luminal)43 (74.1)15 (25.9) Triple Negative31 (44.9)38 (55.1) Vascular invasion19 (42.2)26 (57.8)0.889Clinical Response(%) <0.001Complete61 (75.3)20 (24.7) Partial69 (31.8)148 (68.2) No response6 (20.7)23 (79.3) Progression1 (10)9 (90) Percentage are given per row.
Table 2.Multivariate analysis logistic regression of clinical predictive factors of ypN0. OR95% Confidence Intervalp valueMolecular subtype No-luminal vs Luminal7,7483,913-15,343<0,001Clinical response Response vs not response6,8491,834-25,5710,04OR: Odd ratio. No-luminal includes: luminal B (HER2 +), HER2 Henriched and triple negative. Luminal includes: Luminal A and Luminal B (HER2 -).
Conclusions
A remarkable percentage of N+ became ypN0 after NATC. Molecular subtype and complete clinical response were independent predictive factors of ypN0. We propose to offer the benefit of a targeted axillary procedure in those patients.
Citation Format: Fernandez-Gonzalez S, Falo Zamora C, Nuñez D, Vethencourt A, Pla MJ, Soler T, Guma A, Perez X, Gil M, Ponce J, Garcia A. Predictive factors for considering to avoid axillar lymphadenectomy in selected node positive breast cancer patients after neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-09-04.
Collapse
Affiliation(s)
- S Fernandez-Gonzalez
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Falo Zamora
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - D Nuñez
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Vethencourt
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - MJ Pla
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - T Soler
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Guma
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - X Perez
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M Gil
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - J Ponce
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Garcia
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
33
|
Fernandez S, Garcia A, Vethencourt A, Vazquez S, Petit A, Pla MJ, Ortega R, Pérez J, Gil M, Ponce J, Pernas S, Lopez A, Falo C. Abstract P2-08-58: Prognostic factors of survival in node positive breast cancer patients after neoadjuvant chemotherapy in a large series after 5y follow-up: Can response overcome the poor prognosis of nodal stage? Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Status of the axilla is one of the most significant prognostic factors in breast cancer (BC) patients. On the other hand, response to neoadjuvant chemotherapy (NACT) is related to survival. The aim of the present study is to analyze which prognostic factors impact most on Node positive (N+) BC patient survival after NATC. Material and methods: Retrospective analyses on a series of N+ BC patients treated with NATC based on anthracyclines and taxanes +/- trastuzumab if HER2 positive tumors, between June 2008 and December 2016. Clinical, radiological and pathological outcomes have been evaluated. Residual cancer burden (RCB) 1 and the neoadjuvant response index (INR) 2 have been recorded. Survival was calculated with Kaplan-Meier survival curve since the start of NATC to the first documented disease recurrence (DFS) or death (OS). Hazard ratios (HRs) with 95% CIs were estimated with cox proportional hazards regression analysis and subgroups were compared with a two-sided log-rank test. Results: A total of 345 N+ BC patients were included. Pathological complete response was achieved in 72 (20.8%) patients. After NACT, 137 (39.6%) become ypN0, 9 (2.6%) ypN1 mic, 113 (32.7%) ypN1, 60 (17.3%) ypN2 and 26 (7.6%) N3. Those independent predictive factor of ypN0 were molecular subtype (TN and Her2+) with OR: 7.7, p<0.001 and clinical response with OR 6.88, p: 0.04. At a mean follow-up of 58 months there have been 73 (21.1%) recurrences: 9 (2.3%) local, 45 (13%) systemic, 15 (4.3%) systemic+ local, 3 (0.9%) axilla, 1 (0.3%) supraclavicular. The estimated 5y OS was 87.8%. The univariate analysis according to DSF is detailed in Table1.
Adjusted univariate anaalysis cox regression of clinical and pathological factors of desease free survivalBMI10.989-1.010.963AGE0.9960.953-1.0420.876Dose NATC0.9940.979-1.0080.402Clinical Stage1.4021.077-1.8260.012Rx Image1.260.803-1.9940.311Rx size1.0090.995-1.0240.217Number suspicious ALN1.0950.801-1.4970.57Molecular subtype TN,HER20.8800.534-1.450.616Nottinghan grade1.0460.753-1.4530.789Histological subtype1.4651.044-2.0570.27MOlecular subtype1.1510.956-1.3850.137Vascular invasion1.6761.137-24710.009Clinical response2.3691.709-3.284<0.001Fibrosis tumor bed0.980.972-0.989<0.001Nodal fibrosis>50%1.7950.874-3.6860.111Pathological tumoral response1.6861.175-2.4180.005ypN03.561.853-6.838<0.001NRI0.330.192-0.565<0.001RCB1.2741.106-1.4680.001
In the multivariate model those parameters that were independently prognostic were clinical response HR: 5.44 (IC95% 2.275-13.042, p<0.001) and clinical stage HR: 2.364 (IC95% 1.018-5.490, p: 0.045). Conclusions: The most significant prognostic factor in our N+ series was response to NATC, followed by clinical stage. Those independently predictive factors of axillar response (ypN0) were molecular subtype (TN and Her2+) and clinical response. In conclusion, in those patients with chemo sensitive tumors, lymphadenectomy could be safely spared with a more selective axillary approach.
Citation Format: Fernandez S, Garcia A, Vethencourt A, Vazquez S, Petit A, Pla MJ, Ortega R, Pérez J, Gil M, Ponce J, Pernas S, Lopez A, Falo C. Prognostic factors of survival in node positive breast cancer patients after neoadjuvant chemotherapy in a large series after 5y follow-up: Can response overcome the poor prognosis of nodal stage? [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-58.
Collapse
Affiliation(s)
- S Fernandez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Garcia
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Vethencourt
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - S Vazquez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Petit
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - MJ Pla
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - R Ortega
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - J Pérez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - M Gil
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - J Ponce
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - S Pernas
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - A Lopez
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| | - C Falo
- Hospital Universitari de Bellvitge, Hospitalet, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet, Barcelona, Spain
| |
Collapse
|
34
|
Avila Andrade C, Cunquero Tomas A, Fernandez Diaz A, Meri Abad M, Condori Farfan L, Shaheen I, Cervantes Garcia S, Safont Aguilera M, Iranzo Gonzalez-Cruz V, Sforza V, Caballero C, Godes de Bremond M, Gil M, Aparisi Aparisi F, Blasco Cordellat A, Berrocal Jaime A, Ferrer Bolufer I, Lobo de Mena M, Marcaida Benito G, Camps C. Determination of DPYD polymorphisms before treatment with chemotherapy with a pyrimidine: Should we continue doing it? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O'Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R, Cameron D. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). J Bone Oncol 2018; 13:123-135. [PMID: 30591866 PMCID: PMC6303395 DOI: 10.1016/j.jbo.2018.09.008] [Citation(s) in RCA: 56] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Revised: 09/07/2018] [Accepted: 09/16/2018] [Indexed: 12/28/2022] Open
Abstract
Adjuvant bisphosphonates improve disease outcomes in postmenopausal early breast cancer (EBC) but the long-term effects are poorly described. The AZURE trial (ISRCTN79831382) was designed to determine whether adjuvant zoledronic acid (ZOL) improves disease outcomes in EBC. Previous analyses showed no effect on overall outcomes but identified benefits in postmenopausal women. Here we present the long-term risks and benefits of adjuvant ZOL with 10-years follow-up. Patients and methods 3360 patients with stage II/III breast cancer were included in an academic, international, phase III, randomized, open label trial. Patients were followed up on a regular schedule until 10 years. Patients were randomized on a 1:1 basis to standard adjuvant systemic therapy +/− intravenous ZOL 4 mg every 3–4 weeks x6, and then at reduced frequency to complete 5 years treatment. The primary outcome was disease free survival (DFS). Secondary outcomes included invasive DFS (IDFS), overall survival (OS), sites of recurrence, skeletal morbidity and treatment outcomes according to primary tumor amplification of the transcription factor, MAF. Pre-planned subgroup analyses focused on interactions between menopausal status and treatment effects. Results With a median follow up of 117 months [IQR 70.4–120.4), DFS and IDFS were similar in both arms (HRDFS = 0.94, 95%CI = 0.84–1.06, p = 0.340; HRIDFS = 0.91, 95%CI = 0.82–1.02, p = 0.116). However, outcomes remain improved with ZOL in postmenopausal women (HRDFS = 0.82, 95%CI = 0.67–1.00; HRIDFS = 0.78, 95%CI = 0.64–0.94). In the 79% of tested women with a MAF FISH negative tumor, ZOL improved IDFS (HRIDFS = 0.75, 95%CI = 0.58–0.97) and OS HROS = 0.69, 95%CI = 0.50–0.94), irrespective of menopause. ZOL did not improve disease outcomes in MAF FISH + tumors. Bone metastases as a first DFS recurrence (BDFS) were reduced with ZOL (HRB-DFS = 0.76, 95%CI = 0.63–0.92, p = 0.005). ZOL reduced skeletal morbidity with fewer fractures and skeletal events after disease recurrence. 30 cases of osteonecrosis of the jaw in the ZOL arm (1.8%) have occurred. Conclusions Disease benefits with adjuvant ZOL in postmenopausal early breast cancer persist at 10 years of follow-up. The biomarker MAF identified a patient subgroup that derived benefit from ZOL irrespective of menopausal status.
Collapse
Affiliation(s)
- R E Coleman
- Academic Unit of Clinical Oncology and Sheffield Experimental Cancer Medicine Center, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK
| | - M Collinson
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - W Gregory
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - H Marshall
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - R Bell
- Andrew Love Cancer Centre, Geelong, Australia
| | - D Dodwell
- St James Institute of Oncology, University of Leeds, UK
| | - M Keane
- University Hospital Galway, Ireland
| | - M Gil
- Institut Català d´Oncologia - IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain
| | | | - D Ritchie
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - A Bowman
- Edinburgh Cancer Research Centre, Western General Hospital, University of Edinburgh, UK
| | - V Liversedge
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - R H De Boer
- Royal Melbourne Hospital, Melbourne, Australia
| | | | | | | | - J Joffe
- Huddersfield Royal Infirmary, Huddersfield, UK
| | - J E Brown
- Academic Unit of Clinical Oncology and Sheffield Experimental Cancer Medicine Center, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK
| | - C Wilson
- Academic Unit of Clinical Oncology and Sheffield Experimental Cancer Medicine Center, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK
| | | | | | - R Gomis
- Institute for Research in Biomedicine (IRB Barcelona), Barcelona Science and Technology Institute, CIBERONC and Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - D Cameron
- Edinburgh Cancer Research Centre, Western General Hospital, University of Edinburgh, UK
| |
Collapse
|
36
|
Vescina C, Oderiz R, Bettiol M, Gil M, Morales J, Gatti B, González-Ayala S. Invasive disease caused by H. influenzae non- b serotypes in children. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
37
|
de Zambotti M, Goldstone A, Baker F, Claudatos S, Gil M, Alschuler V, Lim Y, Rosas L, Prouty D, Colrain I. 0141 Effect of Evening Alcohol Intake on Polysomnographic Sleep in Healthy Adults. Sleep 2018. [DOI: 10.1093/sleep/zsy061.140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - F Baker
- SRI International, Menlo Park, CA
| | | | - M Gil
- SRI International, Menlo Park, CA
| | | | - Y Lim
- SRI International, Menlo Park, CA
| | - L Rosas
- SRI International, Menlo Park, CA
| | - D Prouty
- SRI International, Menlo Park, CA
| | | |
Collapse
|
38
|
Goldstone A, Willoughby AR, de Zambotti M, Franzen PL, Sullivan EV, Kardos LM, Claudatos SA, Rosas L, Alschuler VR, Lim Y, Gil M, Hasler BP, Clark DB, Colrain IM, Baker FC. 0257 Age-related Differences in Sleep Spindles and Their Association with Episodic Memory in Adolescents. Sleep 2018. [DOI: 10.1093/sleep/zsy061.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- A Goldstone
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - A R Willoughby
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - M de Zambotti
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - P L Franzen
- University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - E V Sullivan
- Center for Health Sciences, SRI International, Menlo Park, CA
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
| | - L M Kardos
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - S A Claudatos
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - L Rosas
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - V R Alschuler
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - Y Lim
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - M Gil
- Center for Health Sciences, SRI International, Menlo Park, CA
| | - B P Hasler
- University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - D B Clark
- University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - I M Colrain
- Center for Health Sciences, SRI International, Menlo Park, CA
- Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Melbourne, AUSTRALIA
| | - F C Baker
- Center for Health Sciences, SRI International, Menlo Park, CA
- Brain Function Research Group, School of Physiology, University of Witwatersrand, Johannesburg, SOUTH AFRICA
| |
Collapse
|
39
|
Perez S, Iñarrea A, Pérez-Tanoira R, Gil M, López-Díez E, Valenzuela O, Porto M, Alberte-Lista L, Peteiro-Cancelo MA, Treinta A, Carballo R, Reboredo MC, Alvarez-Argüelles ME, Purriños MJ. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain. Virol J 2017; 14:214. [PMID: 29110680 PMCID: PMC5674742 DOI: 10.1186/s12985-017-0879-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Accepted: 10/27/2017] [Indexed: 11/24/2022] Open
Abstract
Background Human papillomavirus (HPV) bivalent and quadrivalent vaccines have been widely implemented in worldwide organized immunization programs. A nonavalent HPV vaccine is now available in several countries. The objective was to describe the fraction of squamous non-invasive high-grade cervical intraepithelial lesions attributable to genotypes targeted by bi-quadrivalent vaccines and by nonavalent vaccine according to age and diagnosis in women living in the city of Vigo (Galicia, Spain). Methods Cervical scrapings (2009–2014) of women with histological diagnosis of cervical intraepithelial neoplasia grade 2 (CIN2, n = 145) and grade 3-carcinoma in situ (CIN3-CIS, n = 244) were tested with Linear Array HPV Genotyping test (Roche diagnostics, Mannheim, Germany). Hierarchical estimation of the fraction attributable to HPV 16/18 or HPV 31/33/45/52/58 detected alone or in combination was calculated. Absolute additional fraction attributable to genotypes targeted by nonavalent vaccine compared to genotypes targeted by bi-quadrivalent vaccines was calculated as the increment of attributable cases with respect to all studied cases. Age group 1, 2 and 3 included women 18 to 34, 35–44 and ≥45 years old, respectively. EPIDAT 3.1 was used. Results Fraction attributable to genotypes targeted by bi-quadrivalent vaccines was 59% CIN2 vs. 69% CIN3-CIS (p < 0.001). It was 63/51/50% of CIN2 and 78/66/45% of CIN3-CIS in age group 1, 2, 3, respectively. Fraction attributable to genotypes targeted by nonavalent vaccine was 86% CIN2 and 86% CIN3-CIS. It was 87/91/75% of CIN2 and 90/86/76% of CIN3-CIS in age group 1, 2, 3, respectively. Fraction attributable to genotypes targeted by these vaccines tended to decrease as age increased (p-trend <0.05). Globally, absolute additional attributable fraction was 16%, 26% and 29% in age group 1, 2 and 3, respectively (p < 0.005). Conclusions Absolute additional fraction of CIN2 and CIN3-CIS attributable to genotypes targeted by nonavalent vaccine was observed in women of any age, especially in those over 35 years old.
Collapse
Affiliation(s)
- S Perez
- Microbiology Department, Institute of Biomedical Research of Vigo, University Hospital of Vigo, Vigo, Spain.
| | - A Iñarrea
- Gynecology Department, University Hospital of Vigo, Vigo, Spain
| | - R Pérez-Tanoira
- Internal Medicine Department, Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - M Gil
- Gynecology Department, University Hospital of Vigo, Vigo, Spain
| | - E López-Díez
- Urology Department, University Hospital of Vigo, Vigo, Spain
| | - O Valenzuela
- Gynecology Department, University Hospital of Vigo, Vigo, Spain
| | - M Porto
- Gynecology Department, University Hospital of Vigo, Vigo, Spain
| | - L Alberte-Lista
- Pathology Department, University Hospital of Vigo, Vigo, Spain
| | | | - A Treinta
- Microbiology Department, Institute of Biomedical Research of Vigo, University Hospital of Vigo, Vigo, Spain
| | - R Carballo
- Microbiology Department, Institute of Biomedical Research of Vigo, University Hospital of Vigo, Vigo, Spain
| | - M C Reboredo
- Gynecology Department, University Hospital of Vigo, Vigo, Spain
| | | | - M J Purriños
- Health and Epidemiology Department. Innovation and management of public health. Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, A Coruña, Spain
| |
Collapse
|
40
|
Gomes L, Pereira M, Martinho C, Machado JP, Gil M, Lopes D, Chemela J, Lopes N, Bastos L. Improving travellers’ referral to travel medicine consultation, in primary care in Portugal, 2017. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx186.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- L Gomes
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - M Pereira
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - C Martinho
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - JP Machado
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - M Gil
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - D Lopes
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - J Chemela
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - N Lopes
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| | - L Bastos
- Public Health Unit, Health Centre Loures Odivelas, Loures, Portugal
| |
Collapse
|
41
|
Gil M, Lopes D, Martinho C, Pereira M, Gomes L, Machado JP, Garcia M, Esteves H. Mental illness decompensation between 2007 and 2016 in a Portuguese municipality. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Gil
- Public Health Unit, Health Centre Loures Odivelas, Odivelas, Portugal
| | - D Lopes
- Public Health Unit, Health Centre Loures Odivelas, Odivelas, Portugal
| | - C Martinho
- Public Health Unit, Health Centre Loures Odivelas, Odivelas, Portugal
| | - M Pereira
- Public Health Unit, Health Centre Loures Odivelas, Odivelas, Portugal
| | - L Gomes
- Public Health Unit, Health Centre Loures Odivelas, Odivelas, Portugal
| | - JP Machado
- Public Health Unit, Health Centre Loures Odivelas, Odivelas, Portugal
| | - M Garcia
- Public Health Unit, Health Centre Loures Odivelas, Odivelas, Portugal
| | - H Esteves
- Public Health and Preventive Medicine Institute, Faculty of Medicine of the University of Lisbon, Odivelas, Portugal
| |
Collapse
|
42
|
Bueno AM, Molina M, Fielding A, Bertran-Alamillo J, Dougherty B, Lai Z, Hodgson D, de las Casas CM, Rowe P, Gil M, Spencer S, Viteri S, Lobera J, Rosell R, Hernandez AG. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Besse B, Garrido Lopez P, Puente J, Cortot A, Olmedo Garcia M, Perol M, Gil M, Chao G, Shahidi J, Bennouna J. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
D’Souza M, Venturato L, Gil M. DEVELOPMENT OF A PERSON-CENTRED COGNITIVE TOOL: HOW TO PROVIDE STRENGTH-BASED MEMORY CARE. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M. D’Souza
- University of Calgary, Calgary, Alberta, Canada
| | | | - M. Gil
- University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
45
|
Mehta R, Kothai Guruswamy Sangameswaran D, Bezbatchenko K, Moore J, Gil M, Khoury T, Baldino C, Caserta J, Fetterly G, Lee K, Adjei A, Opyrchal M. Abstract P6-11-10: Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple negative breast cancer (TNBC) patients have poorer prognosis and there remains a lack of novel targeted therapies for their treatment. PIM2 (Proviral Integrations of Moloney virus 2) belongs to a family of three kinases that have been implicated in the survival and progression of hematologic malignancies and solid tumors. PIM2 has been linked to epithelial to mesenchymal transition in TNBC, which can lead to metastasis and chemotherapeutic resistance. We hypothesized that PIM2 may present as a therapeutic target in TNBC.
Materials and Methods: The study involved both in vitro and in vivo studies involving a novel PIM2 inhibitor JP11646 (obtained from Jasco Pharmaceuticals). TNBC cell lines MDA-MB-231 and BT-549 were obtained for our in vitro studies. Cell viability was evaluated using MTT assay. Western Blot assay was used to evaluate relative protein expression. For in vivo studies, female SCID mice were inoculated in the mammary fat pads with 1 × 106 MDA-MB-231 cells. When tumor volumes reached 100 mm3, the mice were treated with JP11646 at the dosage 15mg/kg intraperitoneally for 2 consecutive days weekly for total of 4 weeks as determined from previous experiments. Control animals received vehicle only. The mice were euthanized once tumors reached ∼1,700 mm3.
Results: BT-549 cells treated in vitro with 3 different available PIM kinase inhibitors AZD 1208, LGB321 and JP12641 showed only modest reduction in cell viability. However, treatment of both MDA-MB-231 and BT-549 with JP 11646 demonstrated significant reduction in cell viability with IC50 ranging from 40 to 71.6 nM. Treatment with JP11646 demonstrated a novel mechanism of action resulting in downregulation of PIM2 in both cell lines. Treatment with JP11646, but not other PIM kinase inhibitors, resulted in activation of apoptosis as measured by cleaved PARP (cPARP) levels. Anti-PIM2 siRNA treatment but not treatment with non-specific PIM kinase inhibitor AZD1208 resulted in cPARP induction. Inhibition of proteolysis by bortezomib resulted in preservation of PIM2 and inhibition of apoptosis as demonstrated by decreased cPARP levels after treatment with JP11646. PIM2 over-expressing clone of MDA-MB-231 cells showed enhanced proliferation and migration properties both in vitro and in vivo.Treatment of mice with orthotopically implanted MDA-MB-231 tumors with JP 11646 resulted in significant reduction in the tumor growth (p=0.0019) and increased overall survival (p=0.018) as compared to control mice.
Conclusions: PIM2 upregulation in TNBC cell line resulted in more aggressive phenotype. JP11646, through novel mechanism of action resulting in degradation of PIM2, showed robust activity in TNBC cell lines both in vitro and in vivo. Further correlative studies in tumors harvested from in vivo experiments are ongoing. These results encourage further exploration of use of JP11646 as a targeted agent in treatment of TNBC.
Citation Format: Mehta R, Kothai Guruswamy Sangameswaran D, Bezbatchenko K, Moore J, Gil M, Khoury T, Baldino C, Caserta J, Fetterly, Jr. G, Lee K, Adjei A, Opyrchal M. Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-10.
Collapse
Affiliation(s)
- R Mehta
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - D Kothai Guruswamy Sangameswaran
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - K Bezbatchenko
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - J Moore
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - M Gil
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - T Khoury
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - C Baldino
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - J Caserta
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - G Fetterly
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - K Lee
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - A Adjei
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| | - M Opyrchal
- Roswell Park Cancer Institute, Buffalo, NY; Univ of Texas Medical School at Houston, Houston, TX; Physician Assistant Practice Program, College of Health Sciences and Professions, Ohio University, Dublin, OH; Jasco Pharmaceuticals, Woburn, MA; Mayo Clinic, Rochester, MN
| |
Collapse
|
46
|
Coleman R, Collinson M, Bell R, Marshall H, Dodwell D, Keane M, Gil M, Gregory W, Cameron D. Abstract P6-17-01: Adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-17-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- R Coleman
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - M Collinson
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - R Bell
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - H Marshall
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - D Dodwell
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - M Keane
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - M Gil
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - W Gregory
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| | - D Cameron
- University of Sheffield, Sheffield, United Kingdom; University of Leeds, Leeds, United Kingdom; AZURE Investigators
| |
Collapse
|
47
|
Ortega A, Domenech M, Falo C, Gil M, Stradella A, Fernandez A, Morilla I, Villanueva R, Castany R, Vazquez S, Molina K, Bergamino M, Navarro V, Pernas S. Abstract P4-21-32: Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The addition of Trastuzumab(T) to chemotherapy (CT) revolutionized HER2-positive breast cancer(BC) and changed its natural history. We reviewed the efficacy of T outside clinical trials in a cancer comprehensive center.
Methods: Ambiespective and descriptive study was conducted in Catalan Institute of Oncology (ICO-Barcelona). Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with LogRank test. The association of clinic-pathological variables and outcome was studied by χ2and Cox proportional hazard analysis.
Results: 430 consecutive early HER2-positive BC patients (pts) were treated with adjuvant/neoadjuvant T and CT from Jan 2005 to Dec 2012. Pt basal characteristics are reported in Table 1. Neoadjuvant treatment was administrated in 230pts (54%) and in 200 (46%) in adjuvancy. Pathological complete response (pCR) in breast and nodes (ypT0/isypN0) was achieved in 48% of pts, with higher rates in hormone receptor (HR)-negative pts (62 vs 37% p=0.0005). Median duration of T: 10.6 months (m). 28%pts treated with neoadjuvant T+CT who achieved a pCR did not receive adjuvant T. Treatment discontinuation: 38pts (8.8%): 27pts due to cardiac toxicity and 4 relapsed during adjuvant T. In 87%pts, neoadjuvant CT was based on anthracyclines(A) and taxanes. Adjuvant CT: A and taxanes in 57.4%; 14%pts FAC, 15.4% A-CMF and 12% TCH. At a median follow-up of 70m (3-135), 44pts (10.4%) had relapsed: 33pts with distant M1, 9pts with only loco-regional disease and 2pts contralateral HER2-positive BC. M1 location: 46% visceral, 34% bone/lymph nodes and 20% in central nervous system (CNS). PFS was 23.4m(0-88); median OS was not reached; estimated 10 years-OS was 86.5%. Pts treated with A and taxanes had a significantly better OS compared to those treated with other CT (113 vs 98m, p= 0.009). Kaplan-Meier curve showed numerically higher relapses at 10 years in HR-positive pts (83 vs 90% p=0.8). Pts with pCR had significantly better OS (113 vs 104m, p=0.006). Pts with CNS-metastases had a significantly worse OS (13 vs 26m,p=0,02) and those with HR-negative (49 vs 24m, p= 0.033).
Conclusion: In everyday clinical practice, recurrences after adjuvant/neoadjuvant trastuzumab in HER2-positive BC were less than described in the T-pivotals trials, with 10% of recurrences at a median of FU of 70m. In our series, estimated 10 years-OS was 86.5%. Pts treated with A and taxanes had a significantly better OS as well as those pts who achieved a pCR. On the contrary, pts with CNS M1 and those with HR-negative had worse prognosis.
Table 1Median age51.9y (27-83)Stage I/II/III106 (25%)/ 226 (52%)/ 97 (23%)HR Positive/ Negative249 (58%)/181 (42%)
Citation Format: Ortega A, Domenech M, Falo C, Gil M, Stradella A, Fernandez A, Morilla I, Villanueva R, Castany R, Vazquez S, Molina K, Bergamino M, Navarro V, Pernas S. Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-32.
Collapse
Affiliation(s)
- A Ortega
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - M Domenech
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - C Falo
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - M Gil
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - A Stradella
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - A Fernandez
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - I Morilla
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - R Villanueva
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - R Castany
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - S Vazquez
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - K Molina
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - M Bergamino
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - V Navarro
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| | - S Pernas
- Catalan Institute of Oncology, Hospitalet del Llobregat, Catalonia/Barcelona, Spain
| |
Collapse
|
48
|
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene 2016; 36:2737-2749. [PMID: 27991928 PMCID: PMC5442428 DOI: 10.1038/onc.2016.427] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 08/31/2016] [Accepted: 10/10/2016] [Indexed: 01/16/2023]
Abstract
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
Collapse
Affiliation(s)
- F Mateo
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - E J Arenas
- Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain
| | - H Aguilar
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Serra-Musach
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - G Ruiz de Garibay
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Boni
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Maicas
- Centre for Applied Medical Research (CIMA) and Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain
| | - S Du
- Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
| | - F Iorio
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.,Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - C Herranz-Ors
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Islam
- Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh
| | - X Prado
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Llorente
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Petit
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Vidal
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Català
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - T Soler
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - G Venturas
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Rojo-Sebastian
- Department of Pathology, MD Anderson Cancer Center, Madrid, Spain
| | - H Serra
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - D Cuadras
- Statistics Unit, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Blanco
- Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Lozano
- Department of Molecular Biology and Biochemistry, Málaga University, and Molecular Oncology Laboratory, Mediterranean Institute for the Advance of Biotechnology and Health Research (IBIMA), University Hospital Virgen de la Victoria, Málaga, Spain
| | - F Canals
- ProteoRed-Instituto de Salud Carlos III, Proteomic Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain
| | - A M Sieuwerts
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - V de Weerd
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - M P Look
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - S Puertas
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - N García
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A S Perkins
- University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY, USA
| | - N Bonifaci
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Skowron
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - L Gómez-Baldó
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - V Hernández
- Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Martínez-Aranda
- Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Martínez-Iniesta
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - X Serrat
- Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - J Cerón
- Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - J Brunet
- Hereditary Cancer Programme, ICO, Girona Biomedical Research Institute (IDIBGI), Girona, Spain
| | - M P Barretina
- Department of Medical Oncology, ICO, IDIBGI, Girona, Spain
| | - M Gil
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - C Falo
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Fernández
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Morilla
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - S Pernas
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M J Plà
- Department of Gynecology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - X Andreu
- Department of Pathology, Parc Taulí Hospital Consortium, Sabadell, Barcelona, Spain
| | - M A Seguí
- Medical Oncology Service, Parc Taulí Hospital Consortium, Sabadell, Barcelona, Spain
| | - R Ballester
- Department of Radiation Oncology, University Hospital Germans Trias i Pujol, ICO, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain
| | - E Castellà
- Department of Pathology, University Hospital Germans Trias i Pujol, ICO, IGTP, Badalona, Barcelona, Spain
| | - M Nellist
- Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - S Morales
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - J Valls
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - A Velasco
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - X Matias-Guiu
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - A Figueras
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J V Sánchez-Mut
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Sánchez-Céspedes
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Cordero
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Gómez-Miragaya
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - L Palomero
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Gómez
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - T F Gajewski
- Departments of Pathology and Medicine, University of Chicago, Chicago, IL, USA
| | - E E W Cohen
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - M Jesiotr
- Department of Pathology, Military Institute of Medicine, Warsaw, Poland
| | - L Bodnar
- Department of Oncology, Military Institute of Medicine, Warsaw, Poland
| | - M Quintela-Fandino
- Breast Cancer Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain
| | - N López-Bigas
- Department of Experimental and Health Sciences, Barcelona Biomedical Research Park, Pompeu Fabra University (UPF), Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - R Valdés-Mas
- Department of Biochemistry and Molecular Biology, University Institute of Oncology of Asturias, University of Oviedo, Oviedo, Spain
| | - X S Puente
- Department of Biochemistry and Molecular Biology, University Institute of Oncology of Asturias, University of Oviedo, Oviedo, Spain
| | - F Viñals
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - O Casanovas
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Graupera
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Hernández-Losa
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - S Ramón Y Cajal
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - L García-Alonso
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK
| | - J Saez-Rodriguez
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK
| | - M Esteller
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.,Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain
| | - A Sierra
- Molecular and Translational Oncology Laboratory, Biomedical Research Center CELLEX-CRBC, Biomedical Research Institute 'August Pi i Sunyer' (IDIBAPS), and Systems Biology Department, Faculty of Science and Technology, University of Vic, Central University of Catalonia, Barcelona, Spain
| | - N Martín-Martín
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain
| | - A Matheu
- Neuro-Oncology Section, Oncology Department, Biodonostia Research Institute, San Sebastian, Spain.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain
| | - A Carracedo
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain.,Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Bilbao, Spain
| | - E González-Suárez
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Nanjundan
- Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, USA
| | - J Cortés
- Department of Medical Oncology, VHIO, Vall d'Hebron University Hospital, Barcelona, Spain
| | - C Lázaro
- Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M D Odero
- Centre for Applied Medical Research (CIMA) and Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain
| | - J W M Martens
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - G Moreno-Bueno
- Department of Biochemistry, Autonomous University of Madrid (UAM), Biomedical Research Institute 'Alberto Sols' (Spanish National Research Council (CSIC)-UAM), Translational Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), and MD Anderson International Foundation, Madrid, Spain
| | - M H Barcellos-Hoff
- Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
| | - A Villanueva
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - R R Gomis
- Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - M A Pujana
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| |
Collapse
|
49
|
Majós C, Cos M, Castañer S, Pons A, Gil M, Fernández-Coello A, Macià M, Bruna J, Aguilera C. Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma. AJNR Am J Neuroradiol 2016; 37:2224-2230. [PMID: 27609621 DOI: 10.3174/ajnr.a4917] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Accepted: 07/01/2016] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Current protocols in patients with glioblastoma include performing an MR examination shortly after surgery and then 2-6 weeks after ending concomitant chemoradiotherapy. The assessment of this first postradiotherapy examination is challenging because the pseudoprogression phenomenon may appear. The aim of this study was to explore if performing an MR examination shortly before radiation therapy (preradiotherapy MR imaging) could improve the radiologic assessment of patients with glioblastoma. MATERIALS AND METHODS A preradiotherapy MR imaging examination was prospectively performed before the start of radiation therapy in 28 consecutive patients with glioblastoma who had undergone surgical resection. Tumor response to chemoradiotherapy was assessed twice: with the early postoperative MR examination as baseline and with the preradiotherapy MR imaging examination as baseline. In addition, tumor growth in the preradiotherapy MR imaging examination was evaluated, and its correlation with patient survival was assessed with Kaplan-Meier analysis and Cox regression. RESULTS Tumor progression after radiation therapy was found in 16 patients, corresponding to pseudoprogression in 7 of them (44%). Four assessments of pseudoprogression switched to partial response or stable disease when preradiotherapy MR imaging was the baseline examination, and the ratio of pseudoprogression was reduced to 25% (3 of 12). Significant differences in survival were found when patients were stratified according to the pattern of tumor growth on preradiotherapy MR imaging (median overall survival "no-growth," 837 days; "focal-growth," 582 days; "global-growth," 344 days; P = .001). CONCLUSIONS Performing a preradiotherapy MR imaging examination may improve the clinical management of patients with glioblastoma by reducing the ratio of pseudoprogression assessments and providing prognostic information.
Collapse
Affiliation(s)
- C Majós
- From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.)
- Centro de Investigación Red en Bioingeniería, Biomateriales y Nanomedicina (C.M., C.A.), Cerdanyola del Vallès, Spain
| | - M Cos
- From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.)
| | - S Castañer
- From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.)
| | - A Pons
- From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.)
| | - M Gil
- Medical Oncology, Institut Català d'Oncologia L'Hospitalet (M.G.)
| | | | - M Macià
- Radiotherapy Oncology, Institut Català d'Oncologia L'Hospitalet (M.M.)
| | - J Bruna
- Neurology (J.B.), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
- Institut d'Investigació Biomèdica de Bellvitge, IDIBELL (J.B.), L'Hospitalet de Llobregat, Spain
| | - C Aguilera
- From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.)
- Centro de Investigación Red en Bioingeniería, Biomateriales y Nanomedicina (C.M., C.A.), Cerdanyola del Vallès, Spain
| |
Collapse
|
50
|
Martinez-Garcia M, Pineda E, Del Barco S, Estival A, Verger E, Marruecos J, Gallego O, Gil M, Fuentes R, de Grigno JCBL, Lucas A, Macia M, Mesía C, Velarde J, García N, Villà S, Balana C. Concomitant chemoradiation (Ch-RT) in elderly newly diagnosed glioblastoma (GB) patients. Updated clinical outcome and molecular characteristics from the GLIOCAT study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|